{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T19:10:10Z","timestamp":1726945810825},"reference-count":35,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Ministry of Education and King Abdulaziz University, Deanship of Scientific Research, Jeddah, Saudi Arabia"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology and Genetic Engineering Reviews"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/02648725.2022.2147683","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T07:47:27Z","timestamp":1673250447000},"page":"421-434","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients"],"prefix":"10.1080","volume":"39","author":[{"given":"Mohd","family":"Wahid","sequence":"first","affiliation":[{"name":"Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju K.","family":"Mandal","sequence":"additional","affiliation":[{"name":"Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad","family":"Jawed","sequence":"additional","affiliation":[{"name":"Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alsulimani","sequence":"additional","affiliation":[{"name":"Medical Laboratory Technology Department, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar M","family":"Hashem","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Harakeh","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, and Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmila","family":"Fagoonee","sequence":"additional","affiliation":[{"name":"Institute of Biostructure and Bioimaging (CNR), Molecular Biotechnology Center, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinaldo","family":"Pellicano","sequence":"additional","affiliation":[{"name":"Unit of Gastroenterology, Molinette Hospital, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafiul","family":"Haque","sequence":"additional","affiliation":[{"name":"Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,1,8]]},"reference":[{"issue":"3","key":"e_1_3_4_2_1","first-page":"185","article-title":"The checkpoint immunotherapy revolution: What started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge","volume":"41","author":"Alexander W.","year":"2016","unstructured":"Alexander, W. (2016). The checkpoint immunotherapy revolution: What started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P & T : A Peer-Reviewed Journal for Formulary Management, 41(3), 185\u2013191. https:\/\/pubmed.ncbi.nlm.nih.gov\/26957887\/","journal-title":"P & T : A Peer-Reviewed Journal for Formulary Management"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.06.009"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1259-z"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S78039"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv414"},{"key":"e_1_3_4_7_1","article-title":"Systemic therapy of metastatic melanoma: On the road to cure","author":"Bhatia S","year":"2015","unstructured":"Bhatia, S, Tykodi, S. S., Lee, S. M., & Thompson, J.A. (2015). Systemic therapy of metastatic melanoma: On the road to cure. Oncology. http:\/\/www.cancernetwork.com\/melanoma\/systemic-therapy-of-metastatic-melanoma-road-cure","journal-title":"Oncology"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_4_9_1","unstructured":"Cancer Facts & Figures. 2013. American Cancer Society. http:\/\/www.cancer.org\/acs\/groups\/content\/@epidemiologysurveilance\/documents\/document\/acspc-036845.pdf."},{"key":"e_1_3_4_10_1","unstructured":"Columbus G. (2017). Nivolumab\/Ipilimumab combo shows modest os benefit in advanced melanoma in updated phase III findings. http:\/\/www.onclive.com\/conference-coverage\/aacr-2017\/nivolumabipilimumab-combo-shows-modest-os-benefit-in-advanced-melanoma-in-updated-phase-iii-findings?p=2."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050092"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.069"},{"issue":"7","key":"e_1_3_4_16_1","first-page":"451","article-title":"Immunotherapy or molecularly targeted therapy: What is the best initial treatment for stage IV BRAF-mutant melanoma?","volume":"13","author":"Gibney G. T.","year":"2015","unstructured":"Gibney, G. T., & Atkins, M. B. (2015). Immunotherapy or molecularly targeted therapy: What is the best initial treatment for stage IV BRAF-mutant melanoma? Clinical Advances in Hematology & Oncology, 13(7), 451\u2013458. https:\/\/pubmed.ncbi.nlm.nih.gov\/26353041\/","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106060-00002"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26724"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"e_1_3_4_21_1","unstructured":"Key Statistics for Melanoma Skin Cancer 2022. https:\/\/www.cancer.org\/cancer\/melanoma-skin-cancer\/about\/key-statistics.html."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.7497\/j.issn.2095-3941.2014.04.002"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0408"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871217"},{"key":"e_1_3_4_28_1","unstructured":"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics). 2017. UpToDate. https:\/\/www.uptodate.com\/contents\/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00649.x"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.01.001"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"e_1_3_4_32_1","volume-title":"Program and Abstracts from the 2011 Annual Meeting of the American Society of Clinical Oncology","author":"Weber J. S.","year":"2011","unstructured":"Weber, J. S., Yu, B., Hall, M., Morelli, D., Yu, D., Zhang, Y., Zhao, X., Sarnaik, A., & Wang, W. (2011). Pharmacodynamic and predictive markers of ipilimumab on melanoma patients\u2019 T-cells. In Program and Abstracts from the 2011 Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois (Abstract2503). ."},{"key":"e_1_3_4_33_1","unstructured":"What is Metastatic Melanoma?. (2020). Oncosec-Immunotherapies. (http:\/\/oncosec.com\/what-is-metastatic-melanoma\/)."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12180"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00040"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"}],"container-title":["Biotechnology and Genetic Engineering Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02648725.2022.2147683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T18:29:53Z","timestamp":1726943393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02648725.2022.2147683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/02648725.2022.2147683"],"URL":"https:\/\/doi.org\/10.1080\/02648725.2022.2147683","relation":{},"ISSN":["0264-8725","2046-5556"],"issn-type":[{"type":"print","value":"0264-8725"},{"type":"electronic","value":"2046-5556"}],"subject":[],"published":{"date-parts":[[2023,1,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tbgr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tbgr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}